# Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

> **NCT07352423** · PHASE1 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** ALXN2230
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07352423
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2026-12-23
- **Final completion:** 2026-12-23
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07352423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07352423, "Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07352423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*